JP2025060882A5 - - Google Patents
Info
- Publication number
- JP2025060882A5 JP2025060882A5 JP2024230070A JP2024230070A JP2025060882A5 JP 2025060882 A5 JP2025060882 A5 JP 2025060882A5 JP 2024230070 A JP2024230070 A JP 2024230070A JP 2024230070 A JP2024230070 A JP 2024230070A JP 2025060882 A5 JP2025060882 A5 JP 2025060882A5
- Authority
- JP
- Japan
- Prior art keywords
- immune effector
- vector
- car
- seq
- effector cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019053156 | 2019-02-08 | ||
| EPPCT/EP2019/053156 | 2019-02-08 | ||
| JP2021546261A JP7663500B2 (ja) | 2019-02-08 | 2020-02-05 | Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 |
| PCT/EP2020/052867 WO2020161186A1 (en) | 2019-02-08 | 2020-02-05 | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546261A Division JP7663500B2 (ja) | 2019-02-08 | 2020-02-05 | Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025060882A JP2025060882A (ja) | 2025-04-10 |
| JP2025060882A5 true JP2025060882A5 (enExample) | 2025-10-07 |
Family
ID=69374312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546261A Active JP7663500B2 (ja) | 2019-02-08 | 2020-02-05 | Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 |
| JP2024230070A Pending JP2025060882A (ja) | 2019-02-08 | 2024-12-26 | Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546261A Active JP7663500B2 (ja) | 2019-02-08 | 2020-02-05 | Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20220184119A1 (enExample) |
| EP (2) | EP4501351A3 (enExample) |
| JP (2) | JP7663500B2 (enExample) |
| KR (1) | KR20210124237A (enExample) |
| CN (1) | CN113727720A (enExample) |
| AU (1) | AU2020217868A1 (enExample) |
| BR (1) | BR112021015429A2 (enExample) |
| CA (1) | CA3129140A1 (enExample) |
| CL (1) | CL2021002067A1 (enExample) |
| CO (1) | CO2021010347A2 (enExample) |
| CU (1) | CU20210067A7 (enExample) |
| DK (1) | DK3920939T3 (enExample) |
| ES (1) | ES3002958T3 (enExample) |
| FI (1) | FI3920939T3 (enExample) |
| HR (1) | HRP20250016T1 (enExample) |
| HU (1) | HUE070174T2 (enExample) |
| IL (1) | IL285122A (enExample) |
| LT (1) | LT3920939T (enExample) |
| MX (1) | MX2021009507A (enExample) |
| PL (1) | PL3920939T3 (enExample) |
| PT (1) | PT3920939T (enExample) |
| RS (1) | RS66364B1 (enExample) |
| SG (1) | SG11202108339TA (enExample) |
| SI (1) | SI3920939T1 (enExample) |
| SM (1) | SMT202500012T1 (enExample) |
| WO (1) | WO2020161186A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2024046572A1 (en) * | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| JP2024545154A (ja) * | 2021-12-09 | 2024-12-05 | ビオンテック・ソシエタス・エウロパエア | Ｃｌｄｎ６発現がんの処置のためのキメラ抗原受容体改変細胞 |
| CN114478802B (zh) * | 2022-01-28 | 2023-05-26 | 郑州大学 | 一种嵌合抗原受体及其应用 |
| CN114410588B (zh) * | 2022-01-29 | 2022-11-04 | 西安电子科技大学 | 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用 |
| CN119654342B (zh) * | 2022-07-28 | 2025-07-18 | 乐普创一生物科技（上海）有限公司 | 抗MerTK抗体及其用途 |
| WO2024022512A1 (en) * | 2022-07-29 | 2024-02-01 | Nanjing Legend Biotech Co., Ltd. | Claudin-6 binding moieties and uses thereof |
| CN120225555A (zh) * | 2022-10-25 | 2025-06-27 | 恺兴生命科技(上海)有限公司 | 抗体及其应用 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2015090230A1 (en) * | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| SI3126381T2 (sl) * | 2014-04-01 | 2022-05-31 | Biontech Cell&Gene Therapies Gmbh | Claudin-6-specifični imunoreceptorji in t-celični epitopi |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| CA3076337A1 (en) * | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
| CN109206524B (zh) * | 2018-09-25 | 2022-04-05 | 山东兴瑞生物科技有限公司 | 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途 |
-
2020
- 2020-02-05 SI SI202030558T patent/SI3920939T1/sl unknown
- 2020-02-05 RS RS20250008A patent/RS66364B1/sr unknown
- 2020-02-05 SM SM20250012T patent/SMT202500012T1/it unknown
- 2020-02-05 HR HRP20250016TT patent/HRP20250016T1/hr unknown
- 2020-02-05 EP EP24208680.9A patent/EP4501351A3/en active Pending
- 2020-02-05 ES ES20702482T patent/ES3002958T3/es active Active
- 2020-02-05 AU AU2020217868A patent/AU2020217868A1/en active Pending
- 2020-02-05 CU CU2021000067A patent/CU20210067A7/es unknown
- 2020-02-05 KR KR1020217024706A patent/KR20210124237A/ko active Pending
- 2020-02-05 WO PCT/EP2020/052867 patent/WO2020161186A1/en not_active Ceased
- 2020-02-05 HU HUE20702482A patent/HUE070174T2/hu unknown
- 2020-02-05 JP JP2021546261A patent/JP7663500B2/ja active Active
- 2020-02-05 FI FIEP20702482.9T patent/FI3920939T3/fi active
- 2020-02-05 US US17/310,463 patent/US20220184119A1/en active Pending
- 2020-02-05 EP EP20702482.9A patent/EP3920939B1/en active Active
- 2020-02-05 BR BR112021015429-9A patent/BR112021015429A2/pt unknown
- 2020-02-05 PT PT207024829T patent/PT3920939T/pt unknown
- 2020-02-05 CN CN202080026088.8A patent/CN113727720A/zh active Pending
- 2020-02-05 CA CA3129140A patent/CA3129140A1/en active Pending
- 2020-02-05 LT LTEPPCT/EP2020/052867T patent/LT3920939T/lt unknown
- 2020-02-05 PL PL20702482.9T patent/PL3920939T3/pl unknown
- 2020-02-05 MX MX2021009507A patent/MX2021009507A/es unknown
- 2020-02-05 SG SG11202108339TA patent/SG11202108339TA/en unknown
- 2020-02-05 DK DK20702482.9T patent/DK3920939T3/da active
-
2021
- 2021-07-25 IL IL285122A patent/IL285122A/en unknown
- 2021-08-05 CO CONC2021/0010347A patent/CO2021010347A2/es unknown
- 2021-08-05 CL CL2021002067A patent/CL2021002067A1/es unknown
-
2024
- 2024-12-26 JP JP2024230070A patent/JP2025060882A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025060882A5 (enExample) | ||
| AU2025204620A1 (en) | Chimeric antigen receptors (CARS), compositions and methods thereof | |
| CN109485734B (zh) | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 | |
| CN113260368B (zh) | 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途 | |
| US12221465B2 (en) | Signaling and antigen-presenting bifunctional receptors (SABR) | |
| JP2020513829A5 (enExample) | ||
| US20240016848A1 (en) | Compositions and Methods for Treating Heart Disease via Redirected T Cell Immunotherapies | |
| JP2016519068A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| CA3133333A1 (en) | Chimeric receptors and methods of use thereof | |
| JP2020513754A5 (enExample) | ||
| US20240101616A1 (en) | Dap10/12 based cars adapted for rush | |
| KR20190102259A (ko) | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 | |
| KR20190138311A (ko) | 종양용해성 바이러스요법 및 면역요법 | |
| CN110257338B (zh) | 嵌合细胞因子受体 | |
| Schafer et al. | KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| AU2023206126B2 (en) | TGF-β receptors and methods of use | |
| CN112029729B (zh) | Cd19和cd22双靶点嵌合抗原受体nk细胞及其应用 | |
| US20230013874A1 (en) | Chimeric antigen receptor | |
| CN114828862A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| Lafont et al. | Characterization of pig-tailed macaque classical MHC class I genes: implications for MHC evolution and antigen presentation in macaques | |
| EP3083674B1 (en) | Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza | |
| CN115124627A (zh) | 一种自分泌IL2Rβγ激动剂的MSLN-CAR-NK细胞及其应用 | |
| JPWO2019236577A5 (enExample) |